Tiny tyrannosaur species discovered in Mongolia
The 'Dragon Prince', whose bones were found in a Mongolian museum, is thought to be about 20 million years older than the Tyrannosaurus Rex and provides a 'missing link' in the evolution of the apex predators.
The skeleton of the Khankhuuluu Mongoliensis demonstrates where the T-Rex got its vicious bite, researchers who 'rediscovered' the species said.
'We see features in its nasal bone that eventually gave tyrannosaurs those very powerful bite forces,' said Jared Voris, from the University of Calgary, the researcher who found the bones.
The fossils were initially found in the early 1970s, but at the time were misidentified as belonging to a different tyrannosaur, Alectrosaurus.
The bones were put away in a drawer at the Institute of Palaeontology of the Mongolian Academy of Sciences in the capital Ulaanbaatar, until they were re-discovered by then-PhD student Mr Voris.
He was handed two plastic tubes full of bones while visiting the institute – and eventually found the fossils were partial skeletons of two different dinosaurs from a new species.
Darla Zelenitsky, a palaeontologist from the University of Calgary, said: 'It is quite possible that discoveries like this are sitting in other museums that just have not been recognised.'
The skeleton shows that the 'Dragon Prince' was about four metres long and weighed only 750kg, according to the findings, published in the academic journal Nature.
An adult T-Rex is believed to have weighed eight times as much.
'They were these really small, fleet-footed predators that lived in the shadows of other apex predatory dinosaurs,' said Dr Voris.
'This discovery shows us that, before tyrannosaurs became the kings, they were princes,' said Zelenitsky.
The finding is considered a 'transitional' fossil and has helped clarify the evolution of the tyrannosaur family, which was 'really messy previously,' said Dr Zelenitsky.
'What makes them so important is their age,' said Stephen Brusatte, a palaeontologist at the University of Edinburgh who was not involved in the study. 'They are about 86 million years old, a good 20 million years older than T-Rex. It has been a frustrating gap in the record.'
The discovery also helps to paint the migration patterns of the tyrannosaurs.
They show that T-Rex's direct ancestors probably migrated from Asia to North America across a land bridge that used to connect Siberia and Alaska 85 million years ago, Dr Zelenitsky said.
Tyrannosaurs then evolved in North America and remained there for the next several million years, she said.
'As the many tyrannosaur species evolved on the continent, they became larger and larger,' said Dr Zelenitsky.
The records are incomplete so scientists are unsure of what happened in Asia 80 million years ago. However, the Khankhuuluu may have later been replaced by larger, more dominant, tyrannosaurs.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
a day ago
- Business Wire
Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Crossbow Therapeutics, Inc., a biotechnology company developing T-Bolt™ therapies, a novel class of T-cell receptor (TCR)-mimetic antibody therapeutics, today announced the nomination of its second development candidate, CBX-663, for the treatment of a broad range of solid tumor and hematologic malignancies. The next-generation T-cell engager targets telomerase reverse transcriptase (TERT), a protein that drives tumor growth and is expressed in up to 95% of cancers. 1,2 CBX-663, a bispecific antibody, binds to TERT-derived peptide human leukocyte antigen (pHLA) complexes on the surface of tumor cells and activates T-cells through a CD3-binding arm. The molecule includes two binding domains for TERT, which increase its ability to engage tumor cells and boost immune activation. 'CBX-663 illustrates how Crossbow's TCR-mimetic platform can unlock new opportunities for antibody-based cancer therapies,' said Briggs Morrison, MD, Chief Executive Officer of Crossbow. 'With strong preclinical performance selectively targeting a pHLA expressed across a broad range of cancers, CBX-663 has the potential to offer a meaningful new treatment option for patients with limited therapeutic options.' In preclinical studies, CBX-663 drove potent, antigen-specific tumor killing across multiple TERT-positive cancer models, with minimal activity against TERT-negative or HLA-mismatched cells. The candidate also demonstrated a favorable safety profile and pharmacokinetics comparable to conventional antibody therapies. Crossbow presented data summarizing the initial characterization of CBX-663 at the 2025 Annual Meeting of the American Association for Cancer Research (AACR). Although TERT resides inside the cell, HLA molecules can present fragments of the protein, known as peptides, on the tumor surface. CBX-663 recognizes one of those peptides, the HLA-A*02:01-restricted TERT540 peptide, and redirects T-cells to attack tumor cells. CBX-663 demonstrated broad cytotoxic activity in vitro in both solid and hematologic cancer cell lines, as well as in primary patient samples ex vivo. In vivo studies further confirmed its anti-tumor efficacy and tolerability. 'CBX-663 reflects the depth of antibody discovery and protein engineering that underpins our T-Bolt™ platform and our ability to generate highly selective, potent molecules against difficult cancer targets,' said Dmitri Wiederschain, PhD, Chief Scientific Officer of Crossbow. 'Its performance in preclinical models reinforces the promise of TCR-mimetic therapeutics, and we're excited to continue advancing this program.' Crossbow discovered and developed CBX-663 through its proprietary T-Bolt™ platform, which uses optimized antibody libraries and precision screening to find high-affinity, specific binders to intracellular tumor antigens displayed as pHLA complexes. The nomination of CBX-663 underscores the platform's potential to deliver a scalable pipeline of T-cell engagers for difficult-to-treat cancers. About Crossbow Therapeutics, Inc. Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company's T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow's efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer. For more information about Crossbow Therapeutics, visit


Hamilton Spectator
2 days ago
- Hamilton Spectator
Litus Announces Field Deployment for its Lithium Extraction Pilot Unit
Calgary, July 23, 2025 (GLOBE NEWSWIRE) — Litus , the critical mineral and battery metal company developing patented, ground-breaking technology to address some of the world's biggest energy challenges, has just announced its lithium extraction pilot unit is now deployed in the field. This milestone represents a major leap in the scale-up of Litus LiNC, the company's patented, one-step, environmental nanotechnology solution for lithium extraction. The Litus LiNC pilot deployment follows the commissioning of Litus's in-house nanomaterial production facility in Calgary, capable of scaling 500 times per day, validated over a twenty-month period. Litus designed and built this facility to ensure access to its proprietary nanocomposite, optimized for each brine. 'We are confident in our technology and our unique ability to extract lithium,' said Dr. Ghada Nafie, CEO and Co-Founder of Litus. 'This pilot represents a key validation step. With every successful scale-up, we move closer to commercial deployment and to redefining what's possible in lithium extraction.' From the Lab to the Field: A Decade of Innovation Almost ten years ago, as the world was embracing the concept of an energy transition, researchers at the University of Calgary were laying the groundwork for the future of energy. At a time when electrification was still emerging and lithium prices were modest, Dr. Nafie, along with co-founders Dr. Pedro Pereira-Almao and Dr. Gerardo Vitale, were developing a nanotechnology solution that later would be used for more efficient and sustainable lithium extraction. Founded in 2019 and launched in 2021, Litus set out with a clear mission: to create a simple, one-step solution that could selectively extract lithium, preserve water resources, and minimize environmental impact. This vision resulted in the patented Litus LiNC, a groundbreaking direct lithium extraction (DLE) solution that has now successfully scaled from lab to field. As lithium prices surged due to rising energy transition targets and unprecedented demand from the automotive and clean tech sectors, many DLE companies emerged with promising lab concepts, but this technology failed to scale. Litus broke that trend. The company's team of world-class researchers and commercialization experts understood the challenge from the beginning: any viable solution had to be robust, scalable, cost-effective, and high-performing. Game-Changing Performance The Litus LiNC pilot unit is a plug-and-play modular system designed for easy integration into existing infrastructure. It requires minimal water and energy, operates with low environmental impact, and extracts lithium with up to 99.5% recovery rates and up to 99% rejection, in brines as low as 30 ppm, for lithium so pure it can easily be upgraded and send to battery manufacturers. This performance makes Litus LiNC uniquely effective in extracting lithium from oil and gas produced water and geothermal brines, in sources previously deemed uneconomical. As the system scales, it offers customers a low-risk, high-reward opportunity to tap into new revenue streams, regardless of market conditions. 'Litus LiNC is profitable when lithium prices are low, and unstoppable when prices are high,' said Dr. Nafie. Litus is more than a technology company — it's a bold vision for the future of clean energy. Built on a foundation of rigorous scientific research, real-world validation, and deep industry experience, Litus is committed to making energy more accessible, abundant, and environmentally responsible. The company has earned international recognition for its innovation, including Cleantech Group's 50 to Watch, Foresight 50, and presentations at ADIPEC, the Chile-Canada Mining Innovation Summit and COP 28. Litus is backed by strategic support from organizations including NRC-IRAP, MICA, Emissions Reduction Alberta, SDTC, Alberta Innovates, The Firehood, MaRS and Foresight. About Litus: Litus is a critical minerals and battery metals company developing patented nanotechnology solutions to meet global energy demands. Its flagship product, Litus LiNC, is a patented, one-step lithium extraction system that economically harvests lithium from low-concentration brines. With operations in North America, Europe, and the Middle East, Litus is accelerating the transition to clean, secure energy systems. Media contact: Dalyce Semko – 403-869-3259 Attachments

Associated Press
2 days ago
- Associated Press
Creative Biolabs Debuts Platforms for Smarter T Cell Stimulation
Creative Biolabs delivers tailored T cell activation solutions using hydrogel matrices, DNA scaffolds, and synthetic systems for precise and efficient immune modulation. Creative Biolabs, the global pioneer in immunotherapy, has developed novel artificial T cell-stimulating platforms —like hydrogel matrices, DNA scaffolds, and synthetic systems—to enhance CAR-T, TCR-T, and adoptive cell therapy research in oncology and immunology. Activation of T cells is also a key issue in cancer immunotherapy, especially as researchers seek more physiologically relevant conditions in which to optimize cell growth, survival, and activity. Creative Biolabs' artificial platforms replicate the most critical aspects of the original lymphoid microenvironment—enabling antigen-specific stimulation and controlled co-signal presentation that reduce activation-induced death and provide for long-lasting immunity. One of the newly announced technologies is a hydrogel-based artificial T cell-stimulating platform, which includes tunable formats such as artificial T cell-stimulating matrices (aTM), artificial lymph node scaffolds (aLN), and immunomodulatory macroporous hydrogels. The platforms enable the possibility of accurately modulating the stiffness of the matrix and biochemical ligand density, triggering localized immune activation with a low off-target effect. Complementing these is the DNA-based platform, which uses self-assembled DNA scaffolds to mimic dendritic cell architectures. With tunable conjugation protein ratios and high surface-to-volume efficiency, researchers can modulate multi-signal stimulation profiles to fit therapeutic design parameters. The platform further improves functional antibody display and allows for scalable stimulation approaches. 'Our tools bridge the gap between engineering precision and biological complexity,' said a Creative Biolabs senior R&D director. 'By simulating the critical immunological signals with synthetic and bioinspired materials, we're empowering scientists to accelerate discovery and improve cell product quality.' In addition to proprietary technology, Creative Biolabs offers end-to-end service customization in processes like DNA scaffold design, molecular engineering, protein functionalization, and in vitro / in vivo testing. Each workflow is supported by GLP-grade quality systems and high-throughput facilities to offer reproducibility and data integrity during the experimental stages. Customers are not only offered cutting-edge platforms but also professional advice and flexible project delivery. Creative Biolabs' team of specialists ranges from immunology, synthetic biology, and materials science to offer cross-functional support that is tailored to achieve every research goal. With applications from antigen-specific T cell screening to potency optimization and the development of novel therapeutics, artificial stimulation platforms hold the promise of transforming the evaluation and scaling of cell therapies. Creative Biolabs is leading innovation in this space, committed to enabling global partners to unlock the full potential of immune-based therapeutics. For additional information or to obtain a custom quote, visit About Creative Biolabs Creative Biolabs is a leader in immunotherapy, delivering customized artificial T cell-activating platforms for CAR-T and TCR-T studies. Their hydrogel, DNA, and synthetic platforms replicate critical immune signals, optimize activation efficiency, and facilitate scalable therapies—uniting engineering accuracy and biological sophistication to propel global cell therapy innovation. Media Contact Company Name: Creative Biolabs Contact Person: Candy Swift Email: Send Email City: Shirley State: New York 11967 Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Creative Biolabs Debuts Platforms for Smarter T Cell Stimulation